Tackling urgent questions in EGFRm NSCLC – 'the issue is treatment sequence'
Whole mutational burden as a predictive marker for response to immunotherapy
Durvalumab improves PFS in stage III lung cancer
The importance of the Phase III JAVELIN LUNG 100 trial in non-small-cell lung cancer
Tremelimumab and durvalumab therapy in lung cancer